Athera, Boehringer Ingelheim enter option agreement on novel therapy

Thursday, June 20, 2013 10:00 AM

Athera Biotechnologies has entered into an option agreement with Boehringer Ingelheim International on a novel preclinical antibody program, which grants Boehringer Ingelheim an exclusive option to acquire the entire program.

Athera’s fully-human monoclonal antibody is intended to treat patients with cardiovascular disease who are at an increased risk of secondary events and death.

Athera will conduct defined preclinical development and a phase I study for the lead antibody, and Boehringer Ingelheim will have an exclusive option to acquire substantially all of Athera’s assets and rights relating to the program.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs